Kent Hawryluk, MBX Biosciences CEO
September 9, 2024 07:35 AM EDT
Financing
Startups

MBX seeks $114M IPO to com­pete with As­cendis and get a long-act­ing GLP-1/GIP pro­drug in­to the clin­ic

Kyle LaHucik

Senior Reporter

MBX Bio­sciences is the lat­est IPO con­tender af­ter sub­mit­ting its pitch for a $114 mil­lion Nas­daq de­but, which will go to­ward …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Mer­ck­'s Eli­av Barr on sub­cu­ta­neous Keytru­da, Sum­mit and deal shop­ping

FDA tells on­col­o­gy com­pa­nies how to run mul­ti-re­gion­al can­cer tri­als with a US ap­proval in mind

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times